Shire Reports on Director/PDMR Share Dealings
The number of ADSs released and the number that lapsed are as follows:
ADSs Released(1) |
ADSs Lapsed(2) |
3,149 |
1,607 |
(1)In accordance with the terms of the deferred share award, upon vesting the deferred ADSs were increased by an amount equivalent to the value of dividends paid by the Company in respect of the deferred ADSs from the date of grant to the date of vesting.
(2)The number of ADSs lapsed is equivalent in value to Ms. Gregory’s tax liability resulting from the release of the deferred ADSs.
No amount was payable by Ms. Gregory on release.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Комментарии